阿德福韦酯联合强肝胶囊治疗乙型肝炎肝硬化26例

Clinical study of Adefovir Dipivoxil combined with Qianggan capsule treating 26 cases with chronic hepatitis-B cirrhosis

目的:观察阿德福韦酯联合强肝胶囊治疗乙型肝炎肝硬化的疗效和安全性。方法:将47例乙型肝炎肝硬化患者随机分为治疗组26例和对照组21例,两组均在保肝、对症等常规治疗基础上接受阿德福韦酯胶囊10mg/d长期治疗,治疗组在对照组基础上联合强肝胶囊3次/d,3粒/d,每服药6d停药1天,疗程为24周。结果:两组患者治疗后Child-Pugh评分下降,肝功能改善,HBV DNA载量下降,配对比较差异有统计学意义(P<0.01)。治疗组肝纤维化指标及脾门厚度的下降值优于对照组,组间比较差异有统计学意义(P<0.01或P<0.05)。结论:阿德福韦酯联合强肝胶囊治疗乙型肝炎肝硬化能显著提高肝纤维化的治疗效果,协同改善肝功能,临床应用安全。

Objective To investigate the efficacy and safety of Adefovir Dipivoxil combined with Qianggan capsule in the treatment of chronic hepatitis - B cirrhosis. Method Forty - seven patients with chronic hepatitis B cirrhosis were randomly divided into the treatment group （ n = 26） and the control group （ n = 21 ）. The two groups were given long - term treatment of Adefovir Dipivoxil （ 10 mg/d） on the basis of conventional therapy, such as liver protection and other symptomatic treatment. The treatment group was treated with Qianggan capsule three times daily on the basis of the control group. The course of treatment was 23 weeks. Results After treatment, the cases in the two groups got decreased Child - Pugh score, improved liver function, declined HBV - DNA load, and the matching difference was significant （P 〈0.01 ）. The decreased value of spleen thickness and hver fibrosis index in the treatment group was superior to the control group, and the difference between the two groups was significant （ P 〈 0.01, P 〈 0.05 ）. Conclusion Adefovir Dipivoxil combined with Qianggan capsule in treating chronic hepatitis - B cirrhosis can significantly enhance the therapeutic effect of liver fibrosis, coordinately improve liver function, and supply security in clinical application.